期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乙型肝炎病毒基因变异及其临床意义 被引量：4

The genetic variability and clinical significance of hepatitis B virus
原文传递
导出
摘要 HBV变异不仅可在慢性感染过程中自然发生，亦可于应用药物或接种疫苗后出现。病毒发生变异后常引起其生物学特征的改变，不仅其自身复制能力可能受到影响，同时可引发对抗病毒药物的耐药及导致严重的不良后果，这给乙型肝炎的预防、诊断和治疗等带来一系列新的问题。因此，加强对HBV变异特征的研究，具有重要的生物学和临床意义。
作者 唐红 陈恩强
机构地区 四川大学华西医院感染性疾病中心
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2009年第3期161-163,共3页 Chinese Journal of Hepatology
关键词 肝炎病毒 乙型 突变 药物耐受 病毒 预后 Hepatitis B virus Mutation Drug resistance,viral Prognosis
分类号 R512.62 [医药卫生—内科学] R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Tang H, Banks KE, Anderson AL, et al. Hepatitis B virus transcription and replication. Drug News Perspect, 2001, 14: 325-334.
  • 2Tacke F, Gehrke C, Luedde T, et al. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol, 2004, 78: 8524-8535.
  • 3Sheldon J, Rodes B, Zoulim F, et al. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat, 2006, 13: 427-434.
  • 4Tang H, Oishi N, Kaneko S, et al. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci, 2006, 97: 977- 983.
  • 5Westland CE, Yang H, Delaney WE 4th, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat, 2005, 12: 67-73.
  • 6Locarnini S, Qi X, Arterbum S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol, 2005, 42(Suppl 2): 17.
  • 7侯金林,孙剑,王程.乙型肝炎病毒耐药变异研究的回顾与展望[J].中华肝脏病杂志,2007,15(1):1-3. 被引量：23
  • 8Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci, 2008, 15: 137-145.

二级参考文献14

  • 1Nowak MA,Bonhoeffer S,Hill AM,et al.Viral dynamics in hepatitis B virus infection.Proc Natl Acad Sci U S A,1996,93:4398-4402.
  • 2Simmonds P.The origin and evolution of hepatitis viruses in humans.J Gen Virol,2001,82(Pt 4):693-712.
  • 3Angus P,Vaughan R,Xiong S,et al.Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Gastroenterology,2003,125:292-297.
  • 4Sheldon J,Camino N,Rodes B,et al.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Antivir Ther,2005,10:727-734.
  • 5Tenney DJ,Levine SM,Rose RE,et al.Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Antimicrob Agents Chemother,2004,48:3498-3507.
  • 6Liaw YF,Chien RN,Yeh CT,et al.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.Hepatology,1999,30:567-572.
  • 7Lok AS,Lai CL,Leung N,et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology,2003,125:1714-1722.
  • 8Dienstag JL,Goldin RD,Heathcote EJ,et al.Histological outcome during long-term lamivudine therapy.Gastroenterology,2003,124:105-117.
  • 9Lin CL,Tsai SL,Lee TH,et al.High frequency of functional antiYMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.Gut,2005,54:152-161.
  • 10Fung SK,Andreone P,Han SH,et al.Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.J Hepatol,2005,43:937-943.

共引文献22

同被引文献39

  • 1彭志高,廖可育.乙型肝炎病毒标志物定量检测与HBV定量关系的研究[J].实用预防医学,2005,12(5):1142-1143. 被引量：3
  • 2邓兰,周陶友,赵连三,杨尧,刘丽,陈敏,陶传敏.乙肝患者血清HBsAg与HBsAb双阳性的特殊模式分析[J].华西医学,2007,22(2):315-315. 被引量：4
  • 3Mirandola S,Campagnolo D,Bortoletto G. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B[J].Journal of Viral Hepatitis,2011,(07):212-216.doi:10.1111/j.1365-2893.2011.01435.x.
  • 4Pollicino T,Maimone S,Isgrb G. Variability of the HBV polgene reverse-transcripmse domain in viral isolates from untreated and LMV-resistant chronic hepatitis B patients[J].Digestive and Liver Disease,2007.A7.doi:10.1016/j.dld.2006.12.037.
  • 5Nguyen MH,Trinh HN,Garcia RT. Prevalence of HBV DNA polymerase (B-DNA Pol) mutations in 345 patients with treatment-naive chronic hepatitis B (CHB)[J].Gastroenterology,2008,(4 Suppl 1):A310.
  • 6CUSTERB, SULLIVAN SD, HAZLET TK, et al. Global epide- miology of hepatitis B virus[ J]. J Clin Gastroenterol, 2004, 38 (Suppl 3) : S158 - S168.
  • 7LOK AS, MCMAHON BJ. Chronic hepatitis B[ J]. Hepatology, 2007, 45(2) : 507 -539.
  • 8WONG VW, CHAN SL, MO F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers [J]. JClin Oncol, 2010, 28(10):1660-1665.
  • 9TAN Y, DING K, SU J, et al. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and recta-analysis [J]. PLoS One, 2012, 7(3) : e32789.
  • 10PAPATHEODRIDIS GV, DIMOU E, DIMAKOPOULOS K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t) ide analog therapy starting with lamivudi- ne [ J ]. Hepatology, 2005, 42 ( 1 ) : 121 - 129.

引证文献4

二级引证文献8

中华肝脏病杂志
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部